Literature DB >> 28640695

Gadolinium Brain Deposition after Macrocyclic Gadolinium Administration: A Pediatric Case-Control Study.

Daniel Tibussek1, Christin Rademacher1, Julian Caspers1, Bernd Turowski1, Jörg Schaper1, Gerald Antoch1, Dirk Klee1.   

Abstract

Purpose To determine whether signal intensity (SI) in T1 sequences as a potential indicator of gadolinium deposition increases after repeated administration of the macrocyclic gadolinium-based contrast agents (GBCAs) gadoteridol and gadoterate meglumine in a pediatric cohort. Materials and Methods This retrospective case-control study of children with brain tumors who underwent nine or more contrast material-enhanced brain magnetic resonance (MR) imaging studies from 2008 to 2015 was approved by the local ethics board. Informed consent was obtained for MR imaging. Twenty-four case patients aged 5-18 years and appropriate control patients with nonpathologic MR neuroimaging findings (and no GBCA administration), matched for age and sex, were inculded. SI was measured on unenhanced T1-weighted MR images for the following five regions of interest (ROIs): the dentate nucleus (DN), pons, substantia nigra (SN), pulvinar thalami, and globus pallidus (GP). Paired t tests were used to compare SI and SI ratios (DN to pons, GP to thalamus) between case patients and control patients. Pearson correlations between relative signal changes and the number of GBCA administrations and total GBCA dose were calculated. Results The mean number of GBCA administrations was 14.2. No significant differences in mean SI for any ROI and no group differences were found when DN-to-pons and GP-to-pulvinar ratios were compared (DN-to-pons ratio in case patients: mean, 1.0083 ± 0.0373 [standard deviation]; DN-to-pons ratio in control patients: mean, 1.0183 ± 0.01917; P = .37; GP-to-pulvinar ratio in case patients: mean, 1.1335 ± 0.04528; and GP-to-pulvinar ratio in control patients: mean, 1.1141 ± 0.07058; P = .29). No correlation was found between the number of GBCA administrations or the total amount of GBCA administered and signal change for any ROI. (Number of GBCA applications: DN: r = -0.254, P = .31; pons: r = -0.097, P = .65; SN: r = -0.194, P = .38; GP: r = -0.175, P = .41; pulvinar: r = -0.067, P = .75; total amount of administered GBCA: DN: r = 0.091, P = .72; pons: r = 0.106, P = .62; SN: r = -0.165, P = .45; GP: r = 0.111, P = .61; pulvinar: r = 0.173, P = .42.) Conclusion Multiple intravenous administrations of these macrocyclic GBCAs in children were not associated with a measurable increase in SI in T1 sequences as an indicator of brain gadolinium deposition detectable by using MR imaging. Additional imaging and pathologic studies are needed to confirm these findings. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28640695     DOI: 10.1148/radiol.2017161151

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  29 in total

Review 1.  Safety issues related to intravenous contrast agent use in magnetic resonance imaging.

Authors:  Skorn Ponrartana; Michael M Moore; Sherwin S Chan; Teresa Victoria; Jonathan R Dillman; Govind B Chavhan
Journal:  Pediatr Radiol       Date:  2021-04-19

2.  Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.

Authors:  A Luana Stanescu; Dennis W Shaw; Nozomu Murata; Kiyoko Murata; Joe C Rutledge; Ezekiel Maloney; Kenneth R Maravilla
Journal:  Pediatr Radiol       Date:  2020-01-27

3.  Half-dose versus full-dose macrocyclic gadolinium at 3-T magnetic resonance imaging in paediatric bone and soft-tissue disease.

Authors:  Giovanna Stefania Colafati; Enrica Rossi; Chiara Carducci; Simone Piga; Ioan Paul Voicu; Angela Mastronuzzi; Paolo Tomà
Journal:  Pediatr Radiol       Date:  2018-07-25

Review 4.  Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.

Authors:  Einat Blumfield; David W Swenson; Ramesh S Iyer; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2019-03-29

Review 5.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

Review 6.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

Review 7.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

8.  Current utilization and procedural practices in pediatric whole-body MRI.

Authors:  Gary R Schooler; Joseph T Davis; Heike E Daldrup-Link; Donald P Frush
Journal:  Pediatr Radiol       Date:  2018-05-02

9.  Surveillance MRI for the detection of locally recurrent Ewing sarcoma seems futile.

Authors:  Ömer Kasalak; Amelie Dammann; Hugo J A Adams; Jelle Overbosch; Rudi A J O Dierckx; Paul C Jutte; Thomas C Kwee
Journal:  Skeletal Radiol       Date:  2018-05-11       Impact factor: 2.199

Review 10.  Gadolinium-based contrast agents in children.

Authors:  Michael N Rozenfeld; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2018-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.